Aclaris Therapeutics Stock News

Aclaris (ACRS) delivered earnings and revenue surprises of 10.87% and 246.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammator

WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammator

Upgrades Wolfe Research upgraded the previous rating for EQT Corp (NYSE:EQT) from Peer Perform to Outperform. EQT earned $1.04 in the third quarter, compared to $0.12 in the year-ago quarter. At the m

These beaten-down stocks have significant upside.

Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55 in the third quarter, compared to $0.43 in the year-ago quarter

Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates fo

- Dr. Neal Walker to transition to Chair of the Board of Directors

WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammator

WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory

Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Upgrades According to JP Morgan, the prior rating for RPM International Inc (NYSE:RPM) was changed from Neutral to Overweight. In the first quarter, RPM International showed an EPS of $1.47, compared